Article Cited by others

MOLECULES OF THE MILLENNIUM

Sofosbuvir: A novel treatment option for chronic hepatitis C infection

Bhatia Harmeet Kaur, Singh Harmanjit, Grewal Nipunjot, Natt Navreet Kaur

Year : 2014| Volume: 5| Issue : 4 | Page no: 278-284

   This article has been cited by
 
1 Exploration of Chiral Lewis Acid Mg 2+ Catalysts in the Synthesis of Aryl Organophosphate Triesters from Phosphorus Oxychloride through a Three-step, Two-pot Substitution Sequence
Emily Granger,Kasia Solomianko,Cori Young,Jeremy Erb
Tetrahedron Letters. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014–2017)
Xiaofang Zuo,Zhipeng Huo,Dongwei Kang,Gaochan Wu,Zhongxia Zhou,Xinyong Liu,Peng Zhan
Expert Opinion on Therapeutic Patents. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
3 Blocking Zika virus vertical transmission
Pinar Mesci,Angela Macia,Spencer M. Moore,Sergey A. Shiryaev,Antonella Pinto,Chun-Teng Huang,Leon Tejwani,Isabella R. Fernandes,Nicole A. Suarez,Matthew J. Kolar,Sandro Montefusco,Scott C. Rosenberg,Roberto H. Herai,Fernanda R. Cugola,Fabiele B. Russo,Nicholas Sheets,Alan Saghatelian,Sujan Shresta,Jeremiah D. Momper,Jair L. Siqueira-Neto,Kevin D. Corbett,Patricia C. B. Beltrão-Braga,Alexey V. Terskikh,Alysson R. Muotri
Scientific Reports. 2018; 8(1)
[Pubmed]  [Google Scholar] [DOI]
4 Quantum Molecular Modelling of Hepatitis C Virus Inhibition through Non-Structural Protein 5B Polymerase Receptor Binding of C 5 -Arylidene Rhodanines
Krishnan Balasubramanian,Vaishali M. Patil
Computational Biology and Chemistry. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Hepatitis E virus replication and interferon responses in human placental cells
Leonard Knegendorf,Svenja A. Drave,Viet Loan Dao Thi,Yannick Debing,Richard J. P. Brown,Florian W. R. Vondran,Kathrin Resner,Martina Friesland,Tanvi Khera,Michael Engelmann,Birgit Bremer,Heiner Wedemeyer,Patrick Behrendt,Johan Neyts,Thomas Pietschmann,Daniel Todt,Eike Steinmann
Hepatology Communications. 2018; 2(2): 173
[Pubmed]  [Google Scholar] [DOI]
6 Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case Reports
Komal Saleem,Braira Wahid,Amjad Ali,Shazia Rafique,Zara Naz,Sana Usman,Muhammad Idrees
Viral Immunology. 2018;
[Pubmed]  [Google Scholar] [DOI]
7 Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds
Ewelina Krol,Gabriela Pastuch-Gawolek,Binay Chaubey,Gabriela Brzuska,Karol Erfurt,Boguslaw Szewczyk
Molecules. 2018; 23(6): 1435
[Pubmed]  [Google Scholar] [DOI]
8 Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study
Zubia Jamil,Yasir Waheed,Maryam Malik,Asghar A. Durrani
PeerJ. 2018; 6: e4853
[Pubmed]  [Google Scholar] [DOI]
9 Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis
Hussien Ahmed,Abdelrahman Ibrahim Abushouk,Attia Attia,Mohamed Gadelkarim,Mohamed Gabr,Ahmed Negida,Mohamed M. Abdel-Daim
Journal of Infection and Public Health. 2017;
[Pubmed]  [Google Scholar] [DOI]
10 The protecting-group free selective 3'-functionalization of nucleosides
Jamie M. McCabe Dunn,Mikhail Reibarkh,Edward C. Sherer,Robert K. Orr,Rebecca T. Ruck,Bryon Simmons,Ana Bellomo
Chem. Sci.. 2017;
[Pubmed]  [Google Scholar] [DOI]
11 Synthetic Approaches for the Preparation of Phosphoramidate Prodrugs of 2'-Deoxypseudoisocytidine
Michaela Serpi,Roberto De Biasi,Fabrizio Pertusati,Magdalena Slusarczyk,Christopher McGuigan
ChemistryOpen. 2017; 6(3): 424
[Pubmed]  [Google Scholar] [DOI]
12 Anti-Nuclear Cytoplasmic Antibody–Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients
Youssef K. Ahmad,Salwa Tawfeek,Mohamed Sharaf-Eldin,Hassan E. Elbatea,Abdelrahman Kobtan,Ferial El-Kalla,Rehab Badawi,Sherief Abd-Elsalam
Hospital Pharmacy. 2017; 52(4): 294
[Pubmed]  [Google Scholar] [DOI]
13 Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient
C. Taibi,M. Tempestilli,A. DæAvolio,A. R. Garbuglia,A. De Nicolò,M. Montalbano,G. DæOffizi
Journal of Clinical Pharmacy and Therapeutics. 2017;
[Pubmed]  [Google Scholar] [DOI]
14 Fluorinated nucleosides as an important class of anticancer and antiviral agents
Alessandra Cavaliere,Katrin C Probst,Andrew D Westwell,Magdalena Slusarczyk
Future Medicinal Chemistry. 2017; 9(15): 1809
[Pubmed]  [Google Scholar] [DOI]
15 Synthesis and antiproliferative evaluation of novel azido nucleosides and their phosphoramidate derivatives
Nuno M. Xavier,Rita Gonçalves-Pereira,Radek Jorda,Eva Reznícková,Vladimír Kryštof,M. Conceição Oliveira
Pure and Applied Chemistry. 2017; 89(9)
[Pubmed]  [Google Scholar] [DOI]
16 The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Carolina Q. Sacramento,Gabrielle R. de Melo,Caroline S. de Freitas,Natasha Rocha,Lucas Villas Bôas Hoelz,Milene Miranda,Natalia Fintelman-Rodrigues,Andressa Marttorelli,André C. Ferreira,Giselle Barbosa-Lima,Juliana L. Abrantes,Yasmine Rangel Vieira,Mônica M. Bastos,Eduardo de Mello Volotão,Estevão Portela Nunes,Diogo A. Tschoeke,Luciana Leomil,Erick Correia Loiola,Pablo Trindade,Stevens K. Rehen,Fernando A. Bozza,Patrícia T. Bozza,Nubia Boechat,Fabiano L. Thompson,Ana M. B. de Filippis,Karin Brüning,Thiago Moreno L. Souza
Scientific Reports. 2017; 7: 40920
[Pubmed]  [Google Scholar] [DOI]
17 Respiratory adverse effects of Sofosbuvir-based regimens for treatment of chronic hepatitis C virus
Dina Abouelkheir Abdalla,Tamer Ali Elhadidy,Tarek Besheer,Raghda Elsayed Farag
Egyptian Journal of Chest Diseases and Tuberculosis. 2017;
[Pubmed]  [Google Scholar] [DOI]
18 Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients
Youssef K. Ahmad,Salwa Tawfeek,Mohamed Sharaf-Eldin,Hassan E. Elbatea,Abdelrahman Kobtan,Ferial El-Kalla,Rehab Badawi,Sherief Abd-Elsalam
Hospital Pharmacy. 2017; 52(4): 294
[Pubmed]  [Google Scholar] [DOI]
19 Synthesis and Biological Evaluation of 6-Substituted-5-Fluorouridine ProTides.
Magdalena Slusarczyk,Salvatore Ferla,Andrea Brancale,Christopher McGuigan
Bioorganic & Medicinal Chemistry. 2017;
[Pubmed]  [Google Scholar] [DOI]
20 Mechanism-Based Solution to the ProTide Synthesis Problem: Selective Access to Sofosbuvir, Acelarin, and INX-08189
Bryon Simmons,Zhuqing Liu,Artis Klapars,Ana Bellomo,Steven M. Silverman
Organic Letters. 2017;
[Pubmed]  [Google Scholar] [DOI]
21 Why Prodrugs and Propesticides Succeed
John E. Casida
Chemical Research in Toxicology. 2017;
[Pubmed]  [Google Scholar] [DOI]
22 Decaying relevance of clinical data towards future decisions in data-driven inpatient clinical order sets
Jonathan H. Chen,Muthuraman Alagappan,Mary K. Goldstein,Steven M. Asch,Russ B. Altman
International Journal of Medical Informatics. 2017; 102: 71
[Pubmed]  [Google Scholar] [DOI]
23 Identification of Peptide Leads to Inhibit Hepatitis C Virus: Inhibitory Effect of Plectasin Peptide Against Hepatitis C Serine Protease
Ammar Y. Abdulrahman,Hussin A. Rothan,Nurshamimi Nor Rashid,See Khai Lim,Wajihah Sakhor,Kah Ching Tee,Teow Chong Teoh,Noorsaadah A. Rahman,Rohana Yusof
International Journal of Peptide Research and Therapeutics. 2016;
[Pubmed]  [Google Scholar] [DOI]
24 Innovative Spectrophotometric Methods for Determination of Newly Discovered Combination for Hepatitis C Treatment
Nada S. Abdelwahab,Nehal F. Farid
Analytical Chemistry Letters. 2016; 6(6): 783
[Pubmed]  [Google Scholar] [DOI]
25 Stability-Indicating Method and LC–MS-MS Characterization of Forced Degradation Products of Sofosbuvir
M. Nebsen,Eman S. Elzanfaly
Journal of Chromatographic Science. 2016;
[Pubmed]  [Google Scholar] [DOI]
26 Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase inhibitor
Debasish Swain,Gananadhamu Samanthula,Shweta Bhagat,P.V. Bharatam,Venkatakrishna Akula,Barij N. Sinha
Journal of Pharmaceutical and Biomedical Analysis. 2016; 120: 352
[Pubmed]  [Google Scholar] [DOI]
27 Dynamic changes in CD45RA-Foxp3high regulatory T-cells in chronic hepatitis C patients during antiviral therapy
Zhiqin Li,Yu Ping,Zujiang Yu,Meng Wang,Dongli Yue,Zhen Zhang,Jianbin Li,Bin Zhang,Xuezhong Shi,Yi Zhang
International Journal of Infectious Diseases. 2016;
[Pubmed]  [Google Scholar] [DOI]
28 Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
B. Kirushnan,M.A. Shujauddin,K. Arumugam,R. Ravichandran
Indian Journal of Transplantation. 2016;
[Pubmed]  [Google Scholar] [DOI]
29 Role of Interferon Gamma and Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 1 Single Nucleotide Polymorphism in Natural Clearance and Treatment Response of HCV Infection
Sikandar Azam,Sobia Manzoor,Muhammad Imran,Javed Ashraf,Sarah Ashraf,Saleha Resham,Eijaz Ghani
Viral Immunology. 2015; 28(4): 222
[Pubmed]  [Google Scholar] [DOI]
30 Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection
Hye Jin Yang,Ju Yeon Ryoo,Bong Kyu Yoo
International Journal of Clinical Pharmacy. 2015; 37(5): 698
[Pubmed]  [Google Scholar] [DOI]

 

Read this article